Claire Mazumdar, Chief Executive Officer at Bicara Therapeutics Inc. (BCAX), sold 15,000 shares at $19.96 ($301K) on 2026-05-18, disclosed to the SEC on 2026-05-20.
Scheduled sale ($301k) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $19.96 | 12,022 | $240K | 79.8% |
| 2 | $20.35 | 2,978 | $61K | 20.2% |
| Total | $20.04 avg | 15,000 | $301K | 100% |
| Filing → |
| BCAX | SELL | 2026-04-20 | $354K | — | Filing → |
| BCAX | SELL | 2026-03-20 | $565K | — | Filing → |
| BCAX | SELL | 2026-03-11 | $1.4M | — | Filing → |